S-A. Im

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

Xin Su, Ping Zhan, Paul R. Gavine et al. · British Journal of Cancer · 2014 · 188 citations · Full text

Medicine, Oncology, Pathology +15

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

Heon‐Jeong Lee, An Na Seo, Eunice Kim et al. · British Journal of Cancer · 2014 · 142 citations · Full text

Medicine, Molecular Medicine, Oncology +16

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim et al. · The Lancet Oncology · 2019 · 130 citations

Medicine, Oncology, Pharmacology +16

Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer

S-W Han, SH Song, E-G Jeong et al. · Oncogene · 2013 · 110 citations

Medicine, Cancer Biology, Oncology +14

Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

HS Rugo, J.P. Delord, S-A. Im et al. · Cancer Research · 2016 · 97 citations

Medicine, Oncology, Pharmacology +17